{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13"],"submitter":["Yu JR"],"pubmed_abstract":["<h4>Introduction</h4>Herd immunity against norovirus (NoV) is poorly understood in terms of its serological properties and vaccine designs. The precise neutralizing serological features of genotype I (GI) NoV have not been studied.<h4>Methods</h4>To expand insights on vaccine design and herd immunity of NoVs, seroprevalence and seroincidence of NoV genotypes GI.2, GI.3, and GI.9 were determined using blockade antibodies based on a 5-year longitudinal serosurveillance among 449 residents in Jidong community.<h4>Results</h4>Correlation between human histo-blood group antigens (HBGAs) and GI NoV, and dynamic and persistency of antibodies were also analyzed. Seroprevalence of GI.2, GI.3, and GI.9 NoV were 15.1%-18.0%, 35.0%-38.8%, and 17.6%-22.0%; seroincidences were 10.0, 21.0, and 11.0 per 1"],"journal":["Frontiers in cellular and infection microbiology"],"pagination":["1258550"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10766831"],"repository":["biostudies-literature"],"pubmed_title":["Serological surveillance of GI norovirus reveals persistence of blockade antibody in a Jidong community-based prospective cohort, 2014-2018."],"pmcid":["PMC10766831"],"pubmed_authors":["Koroma MM","Jing DN","Zhou FY","Yu JX","Du HS","Liang ZY","Dai YC","Wang L","Xie DJ","Yu JR","Zhang XF","Wang Y","Li JH","Xu JY"],"additional_accession":[]},"is_claimable":false,"name":"Serological surveillance of GI norovirus reveals persistence of blockade antibody in a Jidong community-based prospective cohort, 2014-2018.","description":"<h4>Introduction</h4>Herd immunity against norovirus (NoV) is poorly understood in terms of its serological properties and vaccine designs. The precise neutralizing serological features of genotype I (GI) NoV have not been studied.<h4>Methods</h4>To expand insights on vaccine design and herd immunity of NoVs, seroprevalence and seroincidence of NoV genotypes GI.2, GI.3, and GI.9 were determined using blockade antibodies based on a 5-year longitudinal serosurveillance among 449 residents in Jidong community.<h4>Results</h4>Correlation between human histo-blood group antigens (HBGAs) and GI NoV, and dynamic and persistency of antibodies were also analyzed. Seroprevalence of GI.2, GI.3, and GI.9 NoV were 15.1%-18.0%, 35.0%-38.8%, and 17.6%-22.0%; seroincidences were 10.0, 21.0, and 11.0 per 1","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023","modification":"2026-06-03T12:41:05.235Z","creation":"2025-02-19T05:01:14.398Z"},"accession":"S-EPMC10766831","cross_references":{"pubmed":["38188632"],"doi":["10.3389/fcimb.2023.1258550"]}}